Filing Details

Accession Number:
0001179110-21-010819
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-10 16:02:59
Reporting Period:
2021-12-08
Accepted Time:
2021-12-10 16:02:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
744218 Celldex Therapeutics Inc. CLDX In Vitro & In Vivo Diagnostic Substances (2835) 133191702
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1681854 Elizabeth Crowley C/O Celldex Therapeutics, Inc.
53 Frontage Road, Suite 220
Hampton NJ 08827
Sr. Vp &Cpdo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-12-08 4,000 $9.02 8,726 No 4 M Direct
Common Stock Disposition 2021-12-08 4,000 $40.00 4,726 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Incentive Stock Option (Right to Buy) Disposition 2021-12-08 4,000 $0.00 4,000 $9.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
16,000 2028-06-13 No 4 M Direct
Footnotes
  1. On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 300,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
  2. The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 15, 2021.
  3. 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.